International audienceMutiple myeloma (MM) is a neoplasia characterized by the accumulation of malignant plasma cells (PC) in the bone marrow. Although proliferation markers have been studied in MM, none of the current staging systems include them. Moreover, approaches used to analyze proliferation do not separate MM cells (MMCs) from normal PC
Multiple myeloma (MM) is a malign B cell disease cha-racterized by an accumulation of malign plasma ...
A b s t r a c t We have developed a new statistical diagnostic model that examines the correlation b...
The clinical outcome of multiple myeloma (MM) is heterogeneous. A simple and reliable tool is needed...
Despite the high rates of complete response achieved with current treatments, patients with multiple...
Le myélome multiple (MM) est une hémopathie maligne caractérisée par la prolifération d’un clone pla...
Background and aim: The clinical impact of multiparametric flow cytometry (MFC) in multiple myeloma ...
The European Myeloma Network (EMN) organized two flow cytometry workshops. The first aimed to identi...
The Oncology Grand Rounds series is designed to place original reports published in the Journal into...
textabstractThe European Myeloma Network (EMN) organized two flow cytometry workshops. The first aim...
Quantification of bone marrow (BM) plasma cells (PCs) by conventional morphology (CM) is a mandatory...
The minimum residual disease (MRD) for hematopoietic and lymphoid systems tumors is an important com...
In recent years, several studies on large series of multiple myeloma (MM) patients have demonstrated...
The malignant cell phenotype of Multiple Myeloma (MM) remains unclear with studies proposing it to b...
Multiple myeloma (MM) is a malignant plasma cell proliferation Phenotype/cell stem origin Mature dif...
Multiple myeloma (MM) is a malignant plasma cell proliferation (chronic lymphoproliferative disorder...
Multiple myeloma (MM) is a malign B cell disease cha-racterized by an accumulation of malign plasma ...
A b s t r a c t We have developed a new statistical diagnostic model that examines the correlation b...
The clinical outcome of multiple myeloma (MM) is heterogeneous. A simple and reliable tool is needed...
Despite the high rates of complete response achieved with current treatments, patients with multiple...
Le myélome multiple (MM) est une hémopathie maligne caractérisée par la prolifération d’un clone pla...
Background and aim: The clinical impact of multiparametric flow cytometry (MFC) in multiple myeloma ...
The European Myeloma Network (EMN) organized two flow cytometry workshops. The first aimed to identi...
The Oncology Grand Rounds series is designed to place original reports published in the Journal into...
textabstractThe European Myeloma Network (EMN) organized two flow cytometry workshops. The first aim...
Quantification of bone marrow (BM) plasma cells (PCs) by conventional morphology (CM) is a mandatory...
The minimum residual disease (MRD) for hematopoietic and lymphoid systems tumors is an important com...
In recent years, several studies on large series of multiple myeloma (MM) patients have demonstrated...
The malignant cell phenotype of Multiple Myeloma (MM) remains unclear with studies proposing it to b...
Multiple myeloma (MM) is a malignant plasma cell proliferation Phenotype/cell stem origin Mature dif...
Multiple myeloma (MM) is a malignant plasma cell proliferation (chronic lymphoproliferative disorder...
Multiple myeloma (MM) is a malign B cell disease cha-racterized by an accumulation of malign plasma ...
A b s t r a c t We have developed a new statistical diagnostic model that examines the correlation b...
The clinical outcome of multiple myeloma (MM) is heterogeneous. A simple and reliable tool is needed...